Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Keywords: HER2.sup.+ breast cancer, T-DM1, Liquid biopsy, Circulating tumor DNA, Pharmacological resistance

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer 2021-11, Vol.20 (1), p.151-151, Article 151
Hauptverfasser:	Allegretti, Matteo, Fabi, Alessandra, Giordani, Elena, Ercolani, Cristiana, Romania, Paolo, Nisticò, Cecilia, Gasparro, Simona, Barberi, Vittoria, Ciolina, Maria, Pescarmona, Edoardo, Giannarelli, Diana, Ciliberto, Gennaro, Cognetti, Francesco, Giacomini, Patrizio
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine - pharmacology Ado-Trastuzumab Emtansine - therapeutic use Adult Aged Aged, 80 and over Antimitotic agents Antineoplastic agents Biomarkers, Tumor Biopsy Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - etiology Cancer Cancer therapies Care and treatment Circulating tumor DNA Development and progression Disease Progression Drug Resistance, Neoplasm - genetics ErbB-2 protein Female Gene Amplification HER2+ breast cancer Humans Letter to the Editor Leukocytes (mononuclear) Liquid biopsy Liquid Biopsy - methods Middle Aged Mutation Neoplasm Grading Neoplasm Staging Patients Peripheral blood mononuclear cells Pharmacological resistance Plasma Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism T-DM1 Trastuzumab Trends Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Keywords: HER2.sup.+ breast cancer, T-DM1, Liquid biopsy, Circulating tumor DNA, Pharmacological resistance
ISSN:	1476-4598 1476-4598
DOI:	10.1186/s12943-021-01438-z